Echelon Wealth Partners analyst Douglas Loe is holding steady on his investment thesis for clinical stage drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE), …
More Biotech penny stock Antibe Therapeutics has a huge upside: Echelon Videos